Prospective Study to Assess the Efficacy of Letermovir Prophylaxis in Preventing CMV Infection in Lung Transplant Recipients Compared to a Retrospective Cohort Treated With Standard Valganciclovir Prophylaxis for 12 Months (LETERCOR Study)
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Letermovir (Primary) ; Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms LETERCOR
Most Recent Events
- 05 Oct 2023 New trial record